Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | MASP2 | O00187 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655269 | 0.87 | SCN9A (0.59) | SCN9ASCN3AKITSCN4AMASP2 | |
| SCHEMBL23812448 | 0.86 | SCN9A (0.63) | SCN9ASCN3APTPN1PTPN11SCN4A | |
| SCHEMBL20169140 | 0.85 | PTPN1 (0.48) | SCN9APTPN1PTPN11PTPN6AURKA | |
| SCHEMBL23812447 | 0.85 | SCN9A (0.62) | SCN9ASCN3AAURKAMAOBSCN4A | |
| SCHEMBL20501048 | 0.80 | SCN9A (0.64) | SCN9ASCN3ASCN4AMASP2RAB9A | |
| SCHEMBL28364786 | 0.78 | SCN9A (0.62) | SCN9ASCN3ASCN4AMASP2NPC1 | |
| SCHEMBL20169736 | 0.77 | SCN9A (0.61) | SCN9ASCN3AMASP2 | |
| SCHEMBL13655141 | 0.76 | MASP2 (0.58) | SCN9ASCN3AKITMASP2 | |
| SCHEMBL23812470 | 0.75 | PTPN1 (0.46) | PTPN1PTPN11PTPN6AURKAAURKB | |
| SCHEMBL677476 | 0.75 | MEN1 (0.67) | PTPN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975857-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | UNIV NORTH CAROLINA STATE (US) | 2015-07-02 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9005643-B2 | Inhibition of bacterial biofilms with imidazole-phenyl derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009123753-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270475-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | SCN9A 2854/4885SCN3A 3773/4885PTPN1 1006/4885 |
| US-20150183746-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES | TFPI, O60361, PGLS | SCN9A 2854/4885SCN3A 3773/4885PTPN1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.